According to the United Nations website, on February 5, Tedros, Director-General of the World Health Organization, said at a regular press conference in Geneva that the number of coronavirus vaccinations worldwide has exceeded the total number of reported infections, which is both encouraging news, but also highlights the fair score of vaccines again. The importance of matching.
According to previous reports, the latest statistics from Oxford University and other research institutions in the United Kingdom show that with the large-scale implementation of coronavirus vaccination in many countries, the cumulative number of coronavirus vaccines in the world has exceeded the cumulative number of confirmed cases of the novel coronavirus for three days.
Tedros said that more than 75% of coronavirus vaccinations are concentrated in 10 countries, which account for 60% of the global GDP. But at the same time, 2.5 billion people in nearly 130 countries have not received any dose of vaccine.
Tedros reiterated his call to governments to share the surplus vaccine after completing vaccinations against their medical personnel and the elderly population.
“This is the best way to protect their people, because the longer it takes for high-risk groups to vaccinate, the greater the risk of the virus mutation and invalidating the vaccine.”
Tedros also called on relevant enterprises to share information, intellectual property rights and data through the “COVID-19 Technology Acquisition Pool” (C-TAP) provided by WHO, open production licenses, and allow other pharmaceutical manufacturers to produce vaccines in order to expand global production capacity, especially in Asia, Africa and Latina.
The WHO Regional Office for Africa also said on the 4th that about 90 million doses of vaccine provided by the “COVID-19 Vaccine Access Facility” are expected to be shipped to Africa from February and will be able to vaccinate African medical workers and other most vulnerable groups in the first half of 2020, with a vaccination coverage of about 3%.
In addition, AstraZeneca/Oxford University of Oxford’s COVID-19 vaccine is currently undergoing an emergency use permit evaluation by WHO and will begin transportation and distribution once it passes the review.
